Indicator type;Size of the company;Total
Number of companies carrying out R&D in Biotechnology;Less than 250 employees;1.284
Number of companies carrying out R&D in Biotechnology;250 and more employees;160
Number of companies carrying out R&D in Biotechnology;Total;1.444
% Companies by type of biotechnology used: Genetic Code;Less than 250 employees;29,7
% Companies by type of biotechnology used: Genetic Code;250 and more employees;38,6
% Companies by type of biotechnology used: Genetic Code;Total;30,7
% Companies by type of biotechnology used: Functional Units;Less than 250 employees;36,6
% Companies by type of biotechnology used: Functional Units;250 and more employees;45,5
% Companies by type of biotechnology used: Functional Units;Total;37,6
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;Less than 250 employees;20
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;250 and more employees;31,6
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;Total;21,3
% Companies by type of biotechnology used: Bioprocesses;Less than 250 employees;49,5
% Companies by type of biotechnology used: Bioprocesses;250 and more employees;62,6
% Companies by type of biotechnology used: Bioprocesses;Total;50,9
% Companies by type of biotechnology used: Subcellular Organisms;Less than 250 employees;6,8
% Companies by type of biotechnology used: Subcellular Organisms;250 and more employees;18,3
% Companies by type of biotechnology used: Subcellular Organisms;Total;8,1
% Companies by type of biotechnology used: Bioinformatics;Less than 250 employees;22,1
% Companies by type of biotechnology used: Bioinformatics;250 and more employees;26,6
% Companies by type of biotechnology used: Bioinformatics;Total;22,6
% Companies by type of biotechnology used: Nanobiotechnology;Less than 250 employees;9,8
% Companies by type of biotechnology used: Nanobiotechnology;250 and more employees;10,2
% Companies by type of biotechnology used: Nanobiotechnology;Total;9,8
% Companies by type of biotechnology used: Other;Less than 250 employees;16,8
% Companies by type of biotechnology used: Other;250 and more employees;17,2
% Companies by type of biotechnology used: Other;Total;16,9
Companies in which biotechnology activities are: Main and/or exclusive;Less than 250 employees;604
Companies in which biotechnology activities are: Main and/or exclusive;250 and more employees;25
Companies in which biotechnology activities are: Main and/or exclusive;Total;629
Companies in which biotechnology activities are: A secondary business line;Less than 250 employees;215
Companies in which biotechnology activities are: A secondary business line;250 and more employees;47
Companies in which biotechnology activities are: A secondary business line;Total;262
Companies in which biotechnology activities are: A necessary tool for production;Less than 250 employees;465
Companies in which biotechnology activities are: A necessary tool for production;250 and more employees;88
Companies in which biotechnology activities are: A necessary tool for production;Total;553
% Companies by final application areas of biotechnology use: Human Health;Less than 250 employees;44,7
% Companies by final application areas of biotechnology use: Human Health;250 and more employees;41,1
% Companies by final application areas of biotechnology use: Human Health;Total;44,3
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;Less than 250 employees;16,2
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;250 and more employees;12,1
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;Total;15,8
% Companies by final application areas of biotechnology use: Food Products;Less than 250 employees;29,4
% Companies by final application areas of biotechnology use: Food Products;250 and more employees;41,1
% Companies by final application areas of biotechnology use: Food Products;Total;30,7
% Companies by final application areas of biotechnology use: Agriculture and Forestry;Less than 250 employees;25,6
% Companies by final application areas of biotechnology use: Agriculture and Forestry;250 and more employees;20,1
% Companies by final application areas of biotechnology use: Agriculture and Forestry;Total;24,9
% Companies by final application areas of biotechnology use: Environment;Less than 250 employees;17,3
% Companies by final application areas of biotechnology use: Environment;250 and more employees;13,9
% Companies by final application areas of biotechnology use: Environment;Total;16,9
% Companies by final application areas of biotechnology use: Industry;Less than 250 employees;12,5
% Companies by final application areas of biotechnology use: Industry;250 and more employees;13,3
% Companies by final application areas of biotechnology use: Industry;Total;12,6
R&D personnel in Biotechnology (PP);Less than 250 employees;10.452
R&D personnel in Biotechnology (PP);250 and more employees;7.291
R&D personnel in Biotechnology (PP);Total;17.743
R&D personnel in Biotechnology (PP): Research personnel;Less than 250 employees;6.309
R&D personnel in Biotechnology (PP): Research personnel;250 and more employees;3.136
R&D personnel in Biotechnology (PP): Research personnel;Total;9.445
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Less than 250 employees;4.144
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;250 and more employees;4.154
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Total;8.298
R&D personnel in Biotechnology (PP). Women;Less than 250 employees;5.369
R&D personnel in Biotechnology (PP). Women;250 and more employees;4.538
R&D personnel in Biotechnology (PP). Women;Total;9.907
R&D personnel in Biotechnology (PP). Women: Research personnel;Less than 250 employees;3.273
R&D personnel in Biotechnology (PP). Women: Research personnel;250 and more employees;1.832
R&D personnel in Biotechnology (PP). Women: Research personnel;Total;5.104
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Less than 250 employees;2.096
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;250 and more employees;2.707
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Total;4.802
R&D personnel in Biotechnology (FTE);Less than 250 employees;7.232,7
R&D personnel in Biotechnology (FTE);250 and more employees;5.760,8
R&D personnel in Biotechnology (FTE);Total;12.993,4
R&D personnel in Biotechnology (FTE): Research personnel;Less than 250 employees;4.671,5
R&D personnel in Biotechnology (FTE): Research personnel;250 and more employees;2.398,3
R&D personnel in Biotechnology (FTE): Research personnel;Total;7.069,9
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Less than 250 employees;2.561,2
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;250 and more employees;3.362,4
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Total;5.923,6
R&D personnel in Biotechnology (FTE). Women;Less than 250 employees;3.763,9
R&D personnel in Biotechnology (FTE). Women;250 and more employees;3.707,8
R&D personnel in Biotechnology (FTE). Women;Total;7.471,8
R&D personnel in Biotechnology (FTE). Women: Research personnel;Less than 250 employees;2.449,2
R&D personnel in Biotechnology (FTE). Women: Research personnel;250 and more employees;1.421
R&D personnel in Biotechnology (FTE). Women: Research personnel;Total;3.870,1
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Less than 250 employees;1.314,8
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;250 and more employees;2.286,9
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Total;3.601,6
Expenditure on internal R&D in Biotechnology (thousands of euros);Less than 250 employees;691.268
Expenditure on internal R&D in Biotechnology (thousands of euros);250 and more employees;532.533
Expenditure on internal R&D in Biotechnology (thousands of euros);Total;1.223.801
1) By type of expenditure: Current expenditure;Less than 250 employees;614.656
1) By type of expenditure: Current expenditure;250 and more employees;493.534
1) By type of expenditure: Current expenditure;Total;1.108.189
1.1) Labour expenditure of research personnel;Less than 250 employees;221.957
1.1) Labour expenditure of research personnel;250 and more employees;138.965
1.1) Labour expenditure of research personnel;Total;360.922
1.2) Labour expenditure of technical and auxiliary personnel;Less than 250 employees;96.161
1.2) Labour expenditure of technical and auxiliary personnel;250 and more employees;124.379
1.2) Labour expenditure of technical and auxiliary personnel;Total;220.540
1.3) Other current expenditure;Less than 250 employees;296.538
1.3) Other current expenditure;250 and more employees;230.190
1.3) Other current expenditure;Total;526.727
2) By type of expenditure: Capital expenditure;Less than 250 employees;76.612
2) By type of expenditure: Capital expenditure;250 and more employees;39.000
2) By type of expenditure: Capital expenditure;Total;115.612
2.1) Land and buildings;Less than 250 employees;7.247
2.1) Land and buildings;250 and more employees;9.596
2.1) Land and buildings;Total;16.843
2.2) Equipment and tools;Less than 250 employees;37.708
2.2) Equipment and tools;250 and more employees;25.819
2.2) Equipment and tools;Total;63.527
2.3) Acquisition of specific R&D software;Less than 250 employees;2.767
2.3) Acquisition of specific R&D software;250 and more employees;1.191
2.3) Acquisition of specific R&D software;Total;3.959
2.4) Other R&D-specific IP products;Less than 250 employees;28.890
2.4) Other R&D-specific IP products;250 and more employees;2.394
2.4) Other R&D-specific IP products;Total;31.284
1.1) By origin of funds: Own funds;Less than 250 employees;471.465
1.1) By origin of funds: Own funds;250 and more employees;389.138
1.1) By origin of funds: Own funds;Total;860.603
1.2) By origin of funds: Funds from the Business sector;Less than 250 employees;77.630
1.2) By origin of funds: Funds from the Business sector;250 and more employees;50.371
1.2) By origin of funds: Funds from the Business sector;Total;128.002
1.3) By origin of funds: Funds from the Public Administration sector;Less than 250 employees;96.976
1.3) By origin of funds: Funds from the Public Administration sector;250 and more employees;22.523
1.3) By origin of funds: Funds from the Public Administration sector;Total;119.498
1.4) By origin of funds: Funds from the Higher Education sector;Less than 250 employees;647
1.4) By origin of funds: Funds from the Higher Education sector;250 and more employees;0
1.4) By origin of funds: Funds from the Higher Education sector;Total;647
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Less than 250 employees;1.563
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;250 and more employees;11.423
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Total;12.986
1.6) By origin of funds: Funds from the rest of the world;Less than 250 employees;42.988
1.6) By origin of funds: Funds from the rest of the world;250 and more employees;59.078
1.6) By origin of funds: Funds from the rest of the world;Total;102.065
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Less than 250 employees;43.120
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);250 and more employees;80.276
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Total;123.396
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Less than 250 employees;22.993
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;250 and more employees;65.992
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Total;88.985
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Less than 250 employees;20.127
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;250 and more employees;14.284
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Total;34.412
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Less than 250 employees;41,8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;250 and more employees;23,6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Total;39,8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Less than 250 employees;15,2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;250 and more employees;16,4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Total;15,3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Less than 250 employees;22,9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;250 and more employees;17,3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Total;22,3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Less than 250 employees;11,5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;250 and more employees;17
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Total;12,1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Less than 250 employees;17,2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;250 and more employees;15,8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Total;17,1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Less than 250 employees;18,1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;250 and more employees;15,3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Total;17,8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Less than 250 employees;15,4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;250 and more employees;20,3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Total;16
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Less than 250 employees;41,8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;250 and more employees;38,5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Total;41,4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Less than 250 employees;51
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;250 and more employees;44,2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Total;50,2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Less than 250 employees;20,7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;250 and more employees;15,1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Total;20,1
% Companies with international revenues related to biotechnology activities;Less than 250 employees;23
% Companies with international revenues related to biotechnology activities;250 and more employees;20,2
% Companies with international revenues related to biotechnology activities;Total;22,7
% Companies representing international revenues related to biotechnology activities;Less than 250 employees;8,2
% Companies representing international revenues related to biotechnology activities;250 and more employees;1,3
% Companies representing international revenues related to biotechnology activities;Total;2,1
% International revenues related to biotechnology activities distributed in: Revenues from the EU;Less than 250 employees;55,4
% International revenues related to biotechnology activities distributed in: Revenues from the EU;250 and more employees;64,9
% International revenues related to biotechnology activities distributed in: Revenues from the EU;Total;60,6
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;Less than 250 employees;44,6
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;250 and more employees;35,1
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;Total;39,4
% International revenues related to biotechnology activities by classification: International trade in goods and services;Less than 250 employees;93,9
% International revenues related to biotechnology activities by classification: International trade in goods and services;250 and more employees;82,8
% International revenues related to biotechnology activities by classification: International trade in goods and services;Total;87,8
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Less than 250 employees;3,8
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;250 and more employees;15,1
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Total;10,1
% International revenues related to biotechnology activities by classification: Subsidies from external sources;Less than 250 employees;0,7
% International revenues related to biotechnology activities by classification: Subsidies from external sources;250 and more employees;2
% International revenues related to biotechnology activities by classification: Subsidies from external sources;Total;1,4
% International revenues related to biotechnology activities by classification: Other;Less than 250 employees;1,7
% International revenues related to biotechnology activities by classification: Other;250 and more employees;0
% International revenues related to biotechnology activities by classification: Other;Total;0,8